Repligen Corporation (NASDAQ:RGEN) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Repligen Corporation (NASDAQ:RGEN) have been assigned an average rating of “Moderate Buy” from the fourteen brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $177.9167.

Several brokerages have recently issued reports on RGEN. Jefferies Financial Group set a $160.00 target price on Repligen and gave the stock a “hold” rating in a research report on Tuesday, October 28th. Barclays increased their price objective on Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Canaccord Genuity Group boosted their target price on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a report on Wednesday, October 29th. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, Hsbc Global Res raised shares of Repligen to a “strong-buy” rating in a research report on Wednesday, October 1st.

Repligen Stock Performance

Shares of NASDAQ:RGEN opened at $163.86 on Friday. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average price of $159.12 and a 200-day moving average price of $138.12. The company has a market cap of $9.22 billion, a price-to-earnings ratio of 8,197.10, a price-to-earnings-growth ratio of 3.68 and a beta of 1.11. Repligen has a 12 month low of $102.96 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The business had revenue of $188.81 million during the quarter, compared to analyst estimates of $181.23 million. During the same quarter in the prior year, the company posted $0.43 EPS. Repligen’s quarterly revenue was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. As a group, equities analysts anticipate that Repligen will post 1.72 EPS for the current year.

Insider Transactions at Repligen

In other Repligen news, Director Anthony Hunt sold 20,000 shares of the business’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $154.61, for a total value of $3,092,200.00. Following the sale, the director directly owned 80,743 shares of the company’s stock, valued at approximately $12,483,675.23. The trade was a 19.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO James Bylund sold 2,191 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the sale, the chief operating officer directly owned 21,520 shares in the company, valued at approximately $3,254,039.20. This represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 49,657 shares of company stock valued at $7,721,077 in the last ninety days. 1.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Repligen

Institutional investors have recently bought and sold shares of the company. Hsbc Holdings PLC bought a new position in shares of Repligen in the first quarter worth approximately $478,000. Jump Financial LLC purchased a new position in Repligen in the 1st quarter worth approximately $343,000. State of Wyoming lifted its position in Repligen by 5.2% in the 1st quarter. State of Wyoming now owns 2,338 shares of the biotechnology company’s stock valued at $297,000 after acquiring an additional 115 shares in the last quarter. Twin Tree Management LP purchased a new stake in Repligen during the 1st quarter valued at $29,000. Finally, First Light Asset Management LLC boosted its stake in Repligen by 6.5% during the 1st quarter. First Light Asset Management LLC now owns 87,850 shares of the biotechnology company’s stock valued at $11,178,000 after purchasing an additional 5,395 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.